The Institute for Clinical Evaluative Sciences, Toronto, ON, Canada.
Eur J Clin Pharmacol. 2012 Jan;68(1):97-9. doi: 10.1007/s00228-011-1090-8. Epub 2011 Jun 28.
To compare persistence of oxybutynin or tolterodine therapy among older patients newly prescribed one of these drugs.
We conducted a retrospective cohort study of Ontarians aged 66 years and older who were newly prescribed either drug between January 1, 2000 and December 31, 2007. Persistence with treatment was defined on the basis of refills for the drug within a grace period equal to 50% of the prescription duration.
We identified 31,996 patients newly treated with oxybutynin and 24,855 newly treated with tolterodine. After 2 years of follow-up, persistence on oxybutynin (9.4%) was significantly lower than that on tolterodine (13.6%, p < 0.0001). The median time to discontinuation of oxybutynin and tolterodine was 68 and 128 days, respectively.
Our findings suggest that the tolerability of these drugs differs substantially.
比较新处方用奥昔布宁或托特罗定治疗的老年患者的治疗持续时间。
我们对 2000 年 1 月 1 日至 2007 年 12 月 31 日期间新处方用这两种药物的安大略省年龄在 66 岁及以上的患者进行了回顾性队列研究。基于在处方持续时间的 50%的宽限期内对药物进行补充，将治疗的持续性定义为。
我们确定了 31996 名新接受奥昔布宁治疗和 24855 名新接受托特罗定治疗的患者。在 2 年的随访后，奥昔布宁（9.4%）的治疗持续时间明显低于托特罗定（13.6%，p < 0.0001）。奥昔布宁和托特罗定的停药中位数时间分别为 68 天和 128 天。
我们的研究结果表明，这些药物的耐受性有很大差异。
